🇺🇸

US SEC Filing Intelligence

· daily

Insider Trading Pulse — September 23, 2026

The September 23, 2026, insider trading filings reveal a notably high volume of insider selling for executives and directors, with C-suite officers at Medpace Holdings, Sea Ltd, Coinbase Global, and Hims & Hers leading the exits, many under 10b5-1 plans. While selling is dominant, we observe some isolated insider buying from the Chief Growth Officer at Agree Realty at a discounted price and small open-market purchases at Phio Pharmaceuticals and Proficient Auto Logistics. A distinct trend emerges of insider selling across multiple key players in the tech and biotech sectors, signaling possible caution at current valuations. Several notable disposals by major shareholders (KE Holdings) and substantial option exercises followed by sales (Intapp, Nextdoor) add to the cautionary tone. Conversely, we also see option awards and grants at Kamada, Moving iMAGE Technologies, and Great Elm Group, indicating continued alignment and incentive structures. The day is characterized by aggressive profit-taking from high-flying names, which must be weighed against isolated insider confidence in select value positions.

48 high priority 2 medium 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — September 23, 2026

This digest of seven DJIA constituent filings (Sept 23, 2026) reveals a mixed but largely neutral landscape. The dominant theme centers on insider activity at Salesforce, where four executives executed routine share-withholding-for-tax transactions following equity vesting, signaling no directional conviction. A more notable development is an EVP/GC sale of ~$3M at NVIDIA under a 10b5-1 plan, representing a moderate insider-risk flag in an index heavyweight. On the corporate strategy front, McDonald's unveiled its 'McDonald's > NEXT' initiative targeting category share gains and operating margin expansion, though the filing lacked specific financial targets, creating a wait-and-see dynamic. Meanwhile, Visa made a $405M deposit into its litigation escrow, triggering a conversion-rate adjustment that effectively reduces diluted share count by ~1.1M shares—a small but accretive event. The period-over-period data fields in these filings were largely absent of direct financial comparisons (revenue, margins), limiting trend synthesis. Overall, portfolio-level signals are muted, with no major bullish catalysts but a few watch items for risk-conscious investors.

5 high priority 2 medium 7 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — September 23, 2026

The two filings in this digest both involve Nasdaq delistings, highlighting a concentrated distress pattern among micro-cap healthcare/tech companies facing liquidity and compliance crises. SCWorx Corp. (WORX) and Aditxt, Inc. (ADTX) have both been suspended from Nasdaq and now trade on the OTC markets, with SCWorx attempting a last-minute cure via a private placement and Aditxt facing final delisting. Neither filing provided period-over-period financial comparisons, insider trading data, forward-looking guidance, or capital allocation metrics, limiting quantitative trend analysis. The lack of insider activity and financial metrics in both cases amplifies the opacity and risk, as management has not signaled confidence through purchases or provided turnaround targets. The critical development is SCWorx's October 5, 2026 deadline to regain bid price compliance, which represents a binary catalyst for the stock. The overarching theme is that distressed micro-caps are failing to maintain Nasdaq listing standards post-reverse splits, with no visible insider support or credible recovery plans.

2 high priority 2 total filings
· daily

Global High-Priority Regulatory Events — September 23, 2026

This digest covers 40 filings from September 23, 2026, dominated by M&A, insolvency, and delisting events, with a clear thematic split between distressed exits and strategic consolidation. The most critical development is the wave of biotechnology and SPAC delistings, including Theravance Biopharma's Nasdaq exit following its acquisition by Zymeworks, and the forced delisting of Aditxt and ONE Nuclear Energy, signaling a shakeout in the sector. On the M&A front, Sun Communities' $1.03 billion sale of its UK business and Patrick Industries' merger with LCI Industries highlight a trend toward portfolio simplification and scale-building in industrial and housing end-markets. Insolvency proceedings continue for Winsome Yarns, Shirpur Gold Refinery, and Reliance Home Finance, with zero revenue and negative net worth underscoring terminal distress. A notable regulatory rejection occurred at Jindal Leasefin, where the RBI blocked an open offer, halting a change-in-control transaction. Period-over-period data is sparse across filings, but where available, it reveals a pattern of revenue erosion and margin compression in distressed entities, while cash-rich acquirers like Power Grid and Apogee Enterprises are deploying capital for strategic bolt-ons. The overall market implication is a bifurcation: well-capitalized firms are consolidating, while weak balance sheets are being flushed out, creating both risk and opportunity for event-driven investors.

40 high priority 40 total filings
· daily

US SEC Filings Daily Market Digest — September 23, 2026

Today's digest covers 50 filings, revealing a market bifurcated between aggressive capital deployment (M&A, buybacks, debt offerings) and operational headwinds. Key themes include a major $3.0B resort acquisition by **Royal Caribbean** [BULLISH], a transformative voting control transfer at **Cheer Holding** [BULLISH], and a significant cybersecurity incident at **Astrana Health** [RISK]. Period-over-period data shows a mixed earnings season: **Espey Mfg** posted strong profit growth (+37% YoY) and a dividend hike, while **Cracker Barrel** and **General Mills** face top-line pressure. Insider selling was notable at **KE Holdings** ($18M sale) and **Sea Ltd** ($2M sale by CPO), signaling potential caution. Capital allocation trends show a shift toward debt financing, with **Millrose Properties** issuing $1B in senior notes and **HPS** funds reporting elevated leverage ratios. The forward-looking catalyst calendar includes key events like **Ocugen's** shareholder vote on October 5th and **Ferrellgas's** earnings call on September 25th.

23 high priority 27 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — September 23, 2026

This session was extremely quiet for the S&P 500 Consumer Discretionary sector, with only one filing from McDonald's Corporation. The filing is a Regulation FD disclosure of an investor release announcing the company's new 'McDonald's > NEXT' strategic targets, which focus on category share gains, restaurant efficiency, and operating margin expansion. While the filing is forward-looking, it lacks specific financial figures or prior-period comparisons, making it a low-materiality event for immediate portfolio action. The overall sector theme is one of strategic repositioning rather than operational reporting, with no earnings, insider transactions, or capital allocation changes to analyze. The primary takeaway is a long-term strategic pivot from McDonald's that warrants monitoring for future execution details.

1 medium 1 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — September 23, 2026

The three healthcare filings reveal a sector in transition, marked by leadership changes, insider activity, and a major strategic separation. Boston Scientific's executive retirement signals a planned leadership transition, while Gilead's insider transaction reflects routine equity management. The most significant development is Medtronic's exchange offer for MiniMed Group, a high-materiality event that will reshape its diabetes care business. Period-over-period data is limited in these filings, but the absence of negative guidance or deteriorating metrics suggests stable fundamentals. The sector shows a mix of defensive capital returns and strategic portfolio optimization, with Medtronic's spin-off creating a potential catalyst for value realization.

3 high priority 3 total filings
· daily

US Earnings Financial Results SEC Filings — September 23, 2026

This digest covers 9 filings, predominantly from micro-cap and pre-revenue companies, revealing a stark bifurcation in financial health. A core theme is the 'cash burn' narrative, with 4 of 9 companies (Crona, Bakhu, NeoVolta, Amesite) reporting widening net losses and deteriorating cash positions, while only two (ESPEY, 21Shares) show clear positive momentum. Period-over-period comparisons highlight extreme outliers: Amesite's 230% YoY revenue surge contrasts with General Mills' 2.8% decline, and ESPEY's 37.3% net income growth and 75% dividend increase stand out against NeoVolta's 267% net loss widening. The most critical development is the absence of any insider trading activity across all filings, a notable data gap that removes a key conviction signal. For investors, the actionable intelligence lies in identifying the few fundamentally sound operators (ESPEY, General Mills) versus the many cash-burning entities where the risk of equity dilution or insolvency is high.

9 high priority 9 total filings
· daily

US Executive Compensation Proxy SEC Filings — September 23, 2026

The 11 DEF 14A filings in this stream are dominated by routine governance matters (director elections, auditor ratifications) and SPAC extension votes, with only two companies—News Corp and Matrix Service Co—offering substantive financial performance data. News Corp stands out as the clear outlier, reporting strong fiscal 2026 results (revenue +7% YoY to $9.03B, net income +15% to $743M, Total Segment EBITDA +15% to $1.63B) and a massive 4x increase in stock repurchases to $643M, signaling robust capital allocation and management confidence. Conversely, the SPACs (Everest Consolidator, Flag Ship, JAB Acquisition Corp I) and REITs (Power REIT, StratCap Digital, Invesco Real Estate Income Trust) provide no period-over-period financial comparisons, limiting trend analysis. Insider trading activity is absent across all filings, and forward-looking guidance is minimal outside of News Corp’s implied operational momentum. The key portfolio-level pattern is a bifurcation between a high-quality compounder (News Corp) and a sea of non-operational or governance-only entities, making selective focus critical for alpha generation.

11 high priority 11 total filings
· daily

US IPO Pipeline SEC S-1 Filings — September 23, 2026

The single filing in this IPO Pipeline digest—Patrick Industries Inc.'s S-4 registration for its merger with LCI Industries—represents a transformative event in the outdoor recreation and housing components sector, though it is a business combination rather than a traditional IPO. The deal creates a premier component solutions provider with a fixed exchange ratio of 1.2440 Patrick shares per LCI share, implying a valuation that fluctuates with Patrick's stock price. No period-over-period financial trends, insider trading, capital allocation changes, or forward-looking guidance are disclosed in this filing, limiting the depth of quantitative trend analysis. The neutral sentiment and high materiality score (9/10) reflect the deal's structural significance but lack of immediate directional market signal. The combined entity's shareholder composition (52% Patrick, 48% LCI) suggests a near-equal merger, with potential for post-merger synergies and name change catalysts. Investors should monitor shareholder votes and any subsequent financial disclosures for valuation insights.

1 high priority 1 total filings
· daily

US SEC Trading Suspension Halt Orders — September 23, 2026

This intelligence digest covers two Nasdaq-listed micro-cap companies, SCWorx Corp. (WORX) and Aditxt, Inc. (ADTX), both of which received regulatory suspensions and face imminent delisting. The filings reveal a common theme: structural non-compliance with exchange listing rules—specifically the publicly held shares requirement for WORX and broader deficiencies for ADTX—leading to trading suspensions and subsequent transfers to the OTC markets. SCWorx has temporarily staved off delisting via a private placement that cures the share deficiency, and is actively petitioning the Panel for reconsideration, creating a binary catalyst around its October 5, 2026, deadline to also meet the bid price rule. In contrast, Aditxt's path to the OTC is terminal, with Nasdaq having formally filed a Form 25 for removal. From an aggregate perspective, both companies exhibit severe financial distress: no revenue growth or margin trends are reported, insider trading activity is absent, and no capital allocation actions (dividends/buybacks) are occurring. The portfolio-level implication is a heightened risk for investors exposed to distressed micro-caps reliant on reverse splits and dilutive placements to maintain listings, as regulatory scrutiny and time pressures intensify.

2 high priority 2 total filings
· daily

US Executive Officer Management Changes SEC — September 23, 2026

The September 23, 2026 batch of 26 filings is dominated by routine executive and director changes, with several notable high-materiality events creating actionable signals. The most significant development is the CEO appointment at Angi Inc., where a proven turnaround leader (Michael Steib) takes over, signaling a potential strategic pivot and value creation. However, this is counterbalanced by notable CFO/COO departures at TransUnion, Plug Power, and Galaxy Digital, which introduce execution risk for those companies, though the TransUnion guidance reaffirmation partially offsets that concern. Positive board appointments with strong operational backgrounds at Flywire, Five Below, and MeiraGTx provide expertise in critical areas (tech, retail finance, and biopharma portfolio management) that could drive shareholder value. A consistent sector theme is the 'board refresh' at several smaller companies (Terra Innovatum, Hartford Creative, AParadise), suggesting strategic realignments. The data underscores a bifurcated market where companies with stable leadership are reaffirming guidance while others in transition face heightened uncertainty.

26 high priority 26 total filings
· daily

US Corporate Board Director Changes SEC Filings — September 23, 2026

The 26 filings for September 23, 2026, reveal a significant wave of board and C-suite transitions, with a notable pattern of former CFOs and seasoned financial leaders moving into board roles (Farmers & Merchants Bancshares, Five Below, MeiraGTx). The most material event is TransUnion's CFO departure, which is partially mitigated by reaffirmed guidance, while Angi's CEO appointment of Michael Steib signals a strategic pivot toward AI-driven growth. A cluster of biotech and tech companies (MeiraGTx, Flywire, Corcept) are adding directors with deep capital markets and operational expertise, suggesting a focus on commercial readiness. The absence of negative insider selling or guidance cuts across the filings is a positive signal, though several retirements (Boston Scientific, PRA Group, Plug Power) create near-term execution risk. Overall, the digest points to a healthy governance refresh cycle with a tilt toward experienced operators and capital allocators, but investors should monitor the CFO transitions at TransUnion and Galaxy Digital for potential disruption.

26 high priority 26 total filings
· daily

USA Insider Trading Pulse — September 23, 2026

The September 23, 2026 insider trading pulse reveals a pronounced bearish tilt, with 15 sell transactions from C-suite executives and directors across a diverse set of sectors, often executed under pre-arranged 10b5-1 plans. The most material signals are concentrated in high-growth and tech-adjacent names: Medpace Holdings' CEO cashed out $30.8M in a single day, Coinbase's CFO sold $7.35M, and KE Holdings' executive director disposed of $18.1M. While many sales are programmatic, the sheer dollar volume and concentration among top insiders warrants attention. On the bullish side, insider buying remains sparse but notable, with small, opportunistic purchases in real estate (Agree Realty), a distressed biotech (Phio Pharmaceuticals), and a beaten-down logistics name (Proficient Auto Logistics). A significant cluster of option awards at Kamada Ltd and InspireMD suggests these companies are actively incentivizing management, potentially ahead of catalysts. The overall picture is one of significant insider liquidity events against a backdrop of limited conviction buying, creating a cautious near-term outlook for the names involved.

48 high priority 2 medium 50 total filings
· monthly

US Pre-Market SEC Filings Roundup — September 23, 2026

Overnight SEC filings reveal a market bifurcated between aggressive corporate expansion and defensive capital management. Royal Caribbean's $3.0B acquisition of a 50% stake in Sandals/Beaches Resorts and VNET's $659.5M acquisition by PJ Millennium highlight significant M&A activity, while multiple insider sales under 10b5-1 plans (Abacus, Webull, Qualys) signal potential valuation concerns in tech and financial sectors. Positive clinical and regulatory catalysts emerged from Ionis/Roche (sefaxersen Phase 3 hit) and AstraZeneca (EU approval for Trixeo), offering clear upside for healthcare investors. Capital-raising activities are prominent, with Millrose pricing $1.0B in senior notes and HPS funds reporting strong NAV growth and distributions. However, risk flags include Crona Corp's widening losses and zero revenue, Ocugen's shareholder dilution proposal, and Algorhythm's material agreement termination. Sector themes point to continued M&A in travel/leisure, insider selling in growth tech, and robust capital deployment in BDCs and energy infrastructure.

31 high priority 19 medium 50 total filings
· daily

Biotech Small-Cap Approvals — September 22, 2026

The September 22, 2026, small-cap biotech approvals stream delivered three generic/biosimilar-equivalent approvals (EPINEPHRINE from DIFGEN PHARMS, MILNACIPRAN HYDROCHLORIDE from STRIDES PHARMA, and TRETINOIN from ZYDUS LIFESCIENCES), with zero NMEs, zero label expansions, and no true biosimilar designations. The dominant theme is a low-innovation, high-volume genericization wave across established molecules, signaling margin compression rather than growth. The highest-conviction signal is the neutral-to-negative competitive pressure on originators of these mature drugs, as the approvals add supply without novel clinical value. Key watch item is the potential for accelerated price erosion across these three molecules, though commercial impact remains NOT_DISCLOSED. Overall, this is a non-event for pipeline-driven investors, but a modest headwind for originator franchises.

3 total filings
· daily

Big Pharma Approvals — September 22, 2026

This period includes a single label expansion approval for AstraZeneca's CAPIVASERTIB (TRUQAP), categorized as a 'fallback' approval with a bullish signal. No NMEs, biosimilars, or other label expansions were approved, making this a low-volume but still notable event for AstraZeneca's oncology franchise. The dominant signal is the label expansion's potential to broaden CAPIVASERTIB's commercial application, though peak sales, pricing power, and market position remain undisclosed. The key risk is the 'fallback' designation, which may imply a less transformative expansion than a typical label update, limiting investor conviction. Investors should monitor AstraZeneca's subsequent pipeline catalysts to offset this period's thin approval cadence.

1 total filings
· daily

Orphan Drug Approvals — September 22, 2026

During the period of September 22, 2026, one orphan drug approval was recorded, classified as 'Other' with no NMEs, biosimilars, or label expansions. The sole approval was a label expansion for TALETRECTINIB ADIPATE (IBTROZI) by NUVATION, which received a bullish signal. This expansion underscores NUVATION's strategic focus on broadening the clinical utility of its oncology asset, though the lack of disclosed commercial details limits the depth of investment analysis. The dominant therapeutic area theme is oncology, with a single but notable signal of label expansion as a growth strategy. The highest-conviction signal is the label expansion itself, indicating NUVATION's commitment to maximizing the drug's lifecycle value. Key watch items include the absence of disclosed peak sales estimates, exclusivity terms, and pricing power, which are critical for assessing commercial potential.

1 total filings
· daily

New Drug Approvals (Original) — September 22, 2026

The September 22, 2026, FDA approval stream delivered zero NMEs, zero biosimilars (per the mix classification), and three 'Other' approvals—all generic/biosimilar-type products from DIFGEN PHARMS (EPINEPHRINE), STRIDES PHARMA (MILNACIPRAN HYDROCHLORIDE), and ZYDUS LIFESCIENCES (TRETINOIN). This is a low-velocity, low-catalyst period with no therapeutic area clustering; the three approvals span acute allergy, neuropathic pain/depression, and acne/leukemia, respectively. The highest-conviction signal is the TRETINOIN approval by ZYDUS LIFESCIENCES, given the drug's dual dermatology/oncology use and the competitive dynamics in the generic retinoid space, though commercial impact remains NOT_DISCLOSED. Key risk: these are all 'FALLBACK' approvals with no disclosed exclusivity or pricing power, suggesting limited differentiation and potential margin compression. Investors should treat this as a non-event for portfolio positioning, with no bullish or bearish catalysts identified.

3 total filings